Chemistry at the Core
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
Built for Patients
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
Driven by Purpose
We are passionate about using our expertise to address the needs of patients with cancer.
Ruth Adams
Vice President, Clinical Operations
Jason Agostinelli
Finance
Michael Alos
Information Technology
Kari Andrews
Clinical Operations
Kristin Andrews, PhD
Chemistry
Ingrid Armstrong, MS
Clinical Operations
Alex Balcom, MBA, CPA
Chief Financial Officer
Leah Bennis, MPA
Regulatory Affairs
Josh Bergren
Marketing
Jessica Bond
Pharmaceutical Development
Jim Burgeson, MS
Pharmaceutical Development
Kristi Byrnes
Quality
Matthew Campbell
Pharmaceutical Development
Liz Candido
Operations
Stephanie Ceballos
Information Technology
Smruti Chaudhari, PhD
Pharmaceutical Development
Sibao Chen, PhD
Pharmaceutical Development
Paula Chubet
Legal
Christopher Cooper, PhD
Pharmaceutical Development
Leah Crabtree, CPA
Finance
Jess Crespo, CPA
Finance
Steve Critchley
Pharmaceutical Development
Shannon Dauksis, PharmD
Program Management
Rachel DeLaRosa, RN
Medical Writing & Clinical Sciences
Kirsten Duncan, PharmD
Medical Affairs
Karen Ellis
Program Management
Philip Engel
Information Technology
Jenn Fairbanks
Data Management
Wenzhe Fan, PhD
Pharmaceutical Development
Scott Faulhaber, MBA
Clinical Supply Chain
Megan Flynn
Medical Affairs
Jesus Garza, MA
Finance
Baudouin Gerard, PhD
Pharmaceutical Development
Tina Gibson, MS
Quality
Nurisha Gobin, PharmD, MBA, RPh
Regulatory Affairs
Andrew Havens
Legal
Solange Hebert, PharmD, MBA
Pharmacovigilance
Sophie Higgins, MPH
Regulatory Affairs
Rebecca Hoffman
Human Resources
Lisa Holland, MBA, MSN
Market Access
Joshua Horan, PhD
Vice President, Chemistry
Brett Hubbard, RN
Pharmacovigilance
Tina Kehrig
Clinical Operations
Ray Kemper, PhD, DABT
Translational Development
Gloria (Glo) Kennedy, RN
Pharmacovigilance
Jason Kropp
Pharmaceutical Development
Shashank Kulkarni, PhD
Chemistry
Joshua Lance, JD
Legal
Benjamin Lane, PhD
Senior Vice President, Technical Operations
Melissa Laurie, PharmD, MS, MBA
Medical Affairs
Lidya Le
Clinical Operations
Jeffrey Lee
Information Technology
Megan Lichtenfels, CPA
Finance
Jessie Lin
Vice President, Corporate Strategy & Portfolio Management
Chelcie Lister
Corporate Development
Mei Liu, PhD
Biostatistics & Programming
Allison Magnan
Quality
Joseph Magrino, PhD
Biology
Ren Main
Finance
Morgan Maiola, MS
Quality
Sowjanya Mangipudi, MS
Clinical Operations
Steve Margossian, MD, PhD
Clinical Development
Christian Martin
Translational Development
Sammy Al-Masri, MS
Regulatory Affairs
Nathan McConarty, JD
Legal
Scot Mente, PhD
Chemistry
Matthew Metivier, MBA
Senior Vice President,
Human Resources
Human Resources
Deb Miller, MMSc, PhD, JD
Chief Legal Officer
Tuan Minh Nguyen, PhD
Biology
Megan Montgomery, PhD
Medical Affairs
Kevin Newkirk
Program Management
Victoria Nigro, MBA, MS
Clinical Supply Chain
Darlene Noci, ALM
Chief Development Officer
Matthew O’Connor
Data Management
Lorina Ouimette
Pharmacovigilance
Marco Palencia
Clinical Operations
Natalia Pascucci, MBA
Data Management
Meghavi Patel
Pharmaceutical Development
Henry Pelish, PhD
Chief Scientific Officer
James Porter, PhD
Chief Executive Officer
Bob Prytko, MSc
Pharmaceutical Development
Steve Purcell
Biostatistics & Programming
Gosia Riley, MA
Clinical Operations
José Rios Lizarraga, PhD
Pharmaceutical Development
Amy Rochford
Clinical Operations
Catherine Ross, PharmD
Medical Affairs
Paula Rothwell
Clinical Supply Chain
Mikhaila Ruth
Human Resources
Prabjyot Sachdev
Corporate Development
Manoj Samant, PhD
Medical Writing & Clinical Sciences
Danieska Sandino, MBA
Medical Writing & Clinical Sciences
Christine Schneeberg
Clinical Supply Chain
Maureen Secord
Clinical Supply Chain
Jimmy Shannon
Quality
Ally Shou, PhD, JD
Legal
Jacob Sizemore, PhD
Pharmaceutical Development
Greg Smith, MS
Regulatory Affairs
John Soglia, PhD
Senior Vice President, Translational Development
Kevin Staffin
Quality
Yuting Sun, PhD
Biology
Wint Swe, MBBS, MBA
Medical Writing & Clinical Sciences
Anupong Tangpeerachaikul, PhD
Biology
Seth Taylor
Quality
Christopher Turner, MD
Chief Medical Officer
Vivek Upadhyay, MD, MBI
Clinical Development
Virginia Vetter, MS
Regulatory Affairs
Brenda Vienneau, CPA, CMA
Finance
Morgan Walker, PhD
Pharmaceutical Development
Michael Walsh, PhD
Biology
Jason Waters, MBA
Vice President, Commercial
Stacia Wegst-Uhrich, PhD
Pharmaceutical Development
Carla Whalen
Human Resources
Brett Williams, PhD
Chemistry
Lindsey Wilson, MS
Clinical Operations
Jimmy Yung
Finance
Viola Zhu, MD, PhD
Clinical Development
Fareya Zubair, MS
Regulatory Affairs
Our clinical trials
Learn More
A Phase 1/2 study of zidesamtinib (NVL-520) in patients with advanced ROS1-positive NSCLC and other solid tumors.
A Phase 1/2 study of neladalkib (NVL-655) in patients with advanced ALK-positive NSCLC and other solid tumors.
A Phase 3 study of neladalkib (NVL-655) in patients with TKI-naïve ALK-positive NSCLC.
A Phase 1 study of NVL-330 in patients with advanced HER2-altered NSCLC.
